Updates From TEM’s Genomic Peers Guardant Health GH demonstrated strong momentum in the first quarter of 2025, with oncology revenues growing 20% year over year on a 25% increase in test volumes.

Precision oncology specialist Guardant Health (GH 0.64%) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped ...

Guardant's adjusted EBITDA loss was $58.5 million in Q1 and free cash flow was -$67 million. Guardant continues to expect $225-$235 million cash burn in 2025, with roughly $200 million of this ...

Also Read: Medicare To Reimburse Guardant Health’s Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue The collaboration will also allow Pfizer to access Guardant’s liquid biopsy ...

According to the lawsuit filed Feb. 20, Natera recruited former Guardant scientists who transferred thousands of confidential files to develop competing tests. Natera dismissed the allegations as ...

Dive Brief: Guardant Health has accused Natera of poaching its employees and stealing its trade secrets in a lawsuit filed Thursday. The lawsuit claims Nateraaggressively targeted and recruited ...

The initial conversion rate of the New Notes will be 16.0716 shares of Guardant Health’s common stock (the “common stock”), per $1,000 principal amount of New Notes, which represents an ...

Medicare now covers Guardant Reveal for monitoring colorectal cancer recurrence after curative therapy. Analyst sees expanded coverage boosting revenue and improving gross margins by year-end ...

The jury’s finding in favor of Guardant includes the allotment of $175.5 million in punitive damages. As Natera seeks to reverse the ruling, Guardant was much more enthusiastic about the outcome.

The jury awarded Guardant $292.5 million, including $175.5 million in punitive damages, which the company described as one of the largest false advertising verdicts in history.

Guardant Health (NASDAQ: GH) rose 8.4% at least partly after a North California jury awarded the company $292.5 million in a false advertising lawsuit against Natera (NTRA) over Guardant's Reveal ...

Guardant Health said Monday that its colorectal cancer-screening blood test has received approval from the U.S. Food and Drug Administration, sending shares higher.